Summary
- Back in 2019, the Zolgensma approval validated Regenxbio's NAV technology platform for gene delivery. Despite a slow start, Zolgensma recently hit $1B in cumulative sales.
- Regenxbio's organic pipeline is advancing rapidly with RGX-314. And, you can expect an early data release in the next few months.
- Other organic pipeline assets are also progressing at a rapid pace. At the same time, the partnered programs are concurrently maturing.
- I do much more than just articles at Integrated BioSci Investing: Members get access to model portfolios, regular updates, a chat room, and more. Get started today »
"It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price." - Warren Buffett
Amid this raging bull market, you're enjoying the golden ride toward more profits. That's because the coronavirus pandemic has nearly broken all normal market behaviors. In other words, the stock market quickly transitioned from a corona bear in March to an uber bull market within the same year. Though most stocks will rally in a bull market, certain growth stocks will give you outsized gains.
Over many years of doing market research, I've followed many stocks. And, I noticed that niche leaders usually give you the most outsized gains in the long haul. For instance, you saw CRISPR Therapeutics (CRSP) appreciated over 7-folds since I first featured it in 2017. That's the leading company for gene-editing. Now the crowned champion in my book for gene therapy is Regenxbio (RGNX). Intriguingly, Regenxbio hasn't gained that much like CRISPR. Nevertheless, I believe that Regenxbio is a powerful stock whose time has come. In this research, I'll feature a fundamental update on Regenxbio and provide my expectation for this Philip Fisher growth equity.
Figure 1: Regenxbio chart (Source: StockCharts)
